It's How Medicine Should Be®

Physician Profile

-or-

call (888) 352-RUSH for help arranging an appointment

Robin L. Jones, MD

Specialty:
  • Obstetrics and Gynecology
Board Certification:
  • Obstetrics & Gynecology
Faculty Rank: Assistant Professor
Medical or Graduate Education: University of Texas Medical School at Houston
Residency: University at Buffalo School of Medicine and Biomedical Sciences - Obstetrics and Gynecology
Clinical Expertise:
  • Birth control
  • Dyspareunia (painful intercourse)
  • Endometriosis
  • Gestational diabetes
  • Gynecologic procedures
  • Hysterectomy
  • Laparoscopy
  • Menopause
  • Placenta previa
  • Polycystic ovary syndrome (PCOS)
  • Uterine fibroids
Research Interests:
  • Clinical studies of MX6 in cervical intraepithelial neoplasia or carcinoma in situ
  • Biphasic oral contraceptives in women with dysmenorrhea
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

  1. Histology-Driven Therapy: The Importance of Diagnostic Accuracy in Guiding Systemic Therapy of Soft Tissue Tumors.
    Noujaim J, Thway K, Sheri A, Keller C, Jones RL
    Int. J. Surg. Pathol.
    2015 Sep 22
    :.
  2. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
    Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR
    J. Clin. Oncol.
    2015 Sep 14
    :.
  3. Current and advancing systemic treatment options for soft tissue sarcomas.
    Harris SJ, Benson C, Jones RL
    Expert Opin Pharmacother
    2015 Sep
    16(13):2023-37.
  4. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.
    Jones RL, Bendell JC, Smith DC, Diefenbach K, Lettieri J, Boix O, Lockhart AC, O'Bryant C, Moore KN
    Cancer Chemother. Pharmacol.
    2015 Oct
    76(4):777-84.
  5. Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma.
    Attia S, Okuno SH, Robinson SI, Webber NP, Indelicato DJ, Jones RL, Bagaria SP, Jones RL, Sherman C, Kozak KR, Cortese CM, McFarland T, Trent JC, Maki RG
    Rare Tumors
    2015 May 5
    7(2):5992.
  6. The State of Illinois Obstetric Hemorrhage Project: Pre-project and Post-training Examination Scores.
    Wong CA, Scott S, Jones RL, Walzer J, Geller S
    J. Matern. Fetal. Neonatal. Med.
    2015 Mar 10
    :1-21.
  7. The function of repeating: The relation between word class and repetition type in developmental stuttering.
    Buhr AP, Jones RM, Conture EG, Kelly EM
    Int J Lang Commun Disord
    2015 Jul 24
    :.
  8. Synovial sarcoma diagnosis and management in the era of targeted therapies.
    Vlenterie M, Jones RL, van der Graaf WT
    Curr Opin Oncol
    2015 Jul
    27(4):316-22.
  9. Quality of life measures in soft tissue sarcoma.
    Gundle KR, Cizik AM, Jones RL, Davidson DJ
    Expert Rev Anticancer Ther
    2015 Jan
    15(1):95-100.
  10. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.
    Jones RL, Kim ES, Nava-Parada P, Alam S, Johnson FM, Stephens AW, Simantov R, Poondru S, Gedrich R, Lippman SM, Kaye SB, Carden CP
    Clin. Cancer Res.
    2015 Feb 15
    21(4):693-700.
  11. Trabectedin in soft tissue sarcomas.
    Petek BJ, Loggers ET, Pollack SM, Jones RL
    Mar Drugs
    2015 Feb
    13(2):974-83.
  12. Treatment of chest wall sarcomas: a single-institution experience over 20 years.
    Burt A, Berriochoa J, Korpak A, Rodler E, Jones RL, Weisstein J, Patel S
    Am. J. Clin. Oncol.
    2015 Feb
    38(1):80-6.
  13. Redefining the standard of care in metastatic leiomyosarcoma.
    Noujaim J, van der Graaf WT, Jones RL
    Lancet Oncol.
    2015 Apr
    16(4):360-2.
  14. Cardio-oncology: a special focus issue from Future Oncology.
    Jones RL, Sandri MT
    Future Oncol
    2015
    11(14):1993-4.
  15. Cardio-oncology: an ongoing evolution.
    Petek BJ, Greenman C, Herrmann J, Ewer MS, Jones RL
    Future Oncol
    2015
    11(14):2059-66.
  16. A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma.
    Seddon B, Scurr M, Jones RL, Wood Z, Propert-Lewis C, Fisher C, Flanagan A, Sunkersing J, A'Hern R, Whelan J, Judson I
    Clin Sarcoma Res
    2015
    5:13.
  17. Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy.
    Noujaim J, Thway K, Bajwa Z, Bajwa A, Maki RG, Jones RL, Keller C
    Front Oncol
    2015
    5:186.
  18. The Maternal Early Warning Criteria: A Proposal from the National Partnership for Maternal Safety.
    Mhyre JM, D'Oria R, Hameed AB, Lappen JR, Holley SL, Hunter SK, Jones RL, King JC, D'Alton ME
    J Obstet Gynecol Neonatal Nurs
    2014 Sep 9
    :.
  19. Autonomic nervous system activity of preschool-age children who stutter.
    Jones RM, Buhr AP, Conture EG, Tumanova V, Walden TA, Porges SW
    J Fluency Disord
    2014 Sep
    41:12-31.
  20. Success is not final and failure is not fatal.
    Jones RL
    J. Clin. Oncol.
    2014 Oct 20
    32(30):3449-50.
  21. The maternal early warning criteria: a proposal from the national partnership for maternal safety.
    Mhyre JM, D'Oria R, Hameed AB, Lappen JR, Holley SL, Hunter SK, Jones RL, King JC, D'Alton ME
    Obstet Gynecol
    2014 Oct
    124(4):782-6.
  22. Temperament, emotion, and childhood stuttering.
    Jones R, Choi D, Conture E, Walden T
    Semin Speech Lang
    2014 May
    35(2):114-31.
  23. Emotional reactivity and regulation associated with fluent and stuttered utterances of preschool-age children who stutter.
    Jones RM, Conture EG, Walden TA
    J Commun Disord
    2014 Mar-Apr
    48:38-51.
  24. The multidisciplinary management of giant cell tumor of bone.
    Ng VY, Davidson DJ, Kim EY, Pollack SM, Conrad Iii EU, Jones RL
    Expert Rev Anticancer Ther
    2014 Jul
    14(7):783-90.
  25. A contemporary large single-institution evaluation of resected retroperitoneal sarcoma.
    Bremjit PJ, Jones RL, Chai X, Kane G, Rodler ET, Loggers ET, Pollack SM, Pillarisetty VG, Mann GN
    Ann. Surg. Oncol.
    2014 Jul
    21(7):2150-8.
  26. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity.
    Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Muñoz M, Russnes HG, Helland A, Rye IH, Borresen-Dale AL, Maruyama R, van Oudenaarden A, Dowsett M, Jones RL, Reis-Filho J, Gascon P, Gönen M, Michor F, Polyak K
    Cell Rep
    2014 Feb 13
    6(3):514-27.
  27. Systemic therapy in advanced uterine adenosarcoma with sarcomatous overgrowth.
    Schroeder B, Pollack SM, Jones RL
    Gynecol. Oncol.
    2014 Feb
    132(2):513.
  28. A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors.
    Jones RL, Ferrari S, Blay JY, Navid F, Lardelli P, Alfaro V, Siguero M, Soman N, Chawla SP
    Invest New Drugs
    2014 Feb
    32(1):171-7.
  29. Pathological changes in the COPD lung mesenchyme--novel lessons learned from in vitro and in vivo studies.
    Ojo O, Lagan AL, Rajendran V, Spanjer A, Chen L, Sohal SS, Heijink I, Jones R, Maarsingh H, Hackett TL
    Pulm Pharmacol Ther
    2014 Dec
    29(2):121-8.
  30. Analysis of clinical prognostic factors for adult patients with head and neck sarcomas.
    Chang AE, Chai X, Pollack SM, Loggers E, Rodler E, Dillon J, Parvathaneni U, Moe KS, Futran N, Jones RL
    Otolaryngol Head Neck Surg
    2014 Dec
    151(6):976-83.
  31. Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas.
    Greenberger BA, Pulsifer MB, Ebb DH, MacDonald SM, Jones RM, Butler WE, Huang MS, Marcus KJ, Oberg JA, Tarbell NJ, Yock TI
    Int. J. Radiat. Oncol. Biol. Phys.
    2014 Aug 1
    89(5):1060-8.
  32. Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics.
    Jour G, Scarborough JD, Jones RL, Loggers E, Pollack SM, Pritchard CC, Hoch BL
    Hum. Pathol.
    2014 Aug
    45(8):1563-71.
  33. PM00104 (Zalypsis®): a marine derived alkylating agent.
    Petek BJ, Jones RL
    Molecules
    2014
    19(8):12328-35.
  34. Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells.
    Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M, Conrad EU, Eary JF, Shibuya KC, Warren EH, Carstens JN, Heimfeld S, Riddell SR, Yee C
    J Immunother Cancer
    2014
    2(1):36.
  35. KIT signaling regulates primordial follicle formation in the neonatal mouse ovary.
    Jones RL, Pepling ME
    Dev. Biol.
    2013 Oct 1
    382(1):186-97.
  36. New drugs and clinical trial design in advanced sarcoma: have we made any progress?
    Constantinidou A, Miah A, Pollack S, Jones RL
    Future Oncol
    2013 Oct
    9(10):1409-11.
  37. The use of radiofrequency ablation in gastrointestinal stromal tumor.
    Pollack SM, Pillarisetty VG, Padia SA, Jones RL
    J Vasc Interv Radiol
    2013 May
    24(5):751.
  38. Delayed development of a rhabdomyosarcoma following radiation for a spinal cord glioma.
    Marzbani E, Mazbani E, Jones RL, Fink J, Chamberlain MC
    J. Neurooncol.
    2013 Mar
    112(1):115-8.
  39. A reconsideration of Gallicolumba (Aves: Columbidae) relationships using fresh source material reveals pseudogenes, chimeras, and a novel phylogenetic hypothesis.
    Moyle RG, Jones RM, Andersen MJ
    Mol. Phylogenet. Evol.
    2013 Mar
    66(3):1060-6.
  40. Bone cancer.
    Biermann JS, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Butrynski JE, Cheong D, Chow W, Curry WT, Frassica DA, Frassica FJ, Hande KR, Hornicek FJ, Jones RL, Mayerson J, McGarry SV, McGrath B, Morris CD, O'Donnell RJ, Randall RL, Santana VM, Satcher RL, Siegel HJ, von Mehren M, Bergman MA, Sundar H,
    J Natl Compr Canc Netw
    2013 Jun 1
    11(6):688-723.
  41. Impact of (18)F-FDG PET/CT imaging in therapeutic decisions for malignant solitary fibrous tumor of the pelvis.
    Yan J, Jones RL, Lewis DH, Eary JF
    Clin Nucl Med
    2013 Jun
    38(6):453-5.
  42. Clinical benefit of trabectedin in uterine adenosarcoma.
    Schroeder BA, Rodler ET, Loggers ET, Pollack SM, Jones RL
    Med. Oncol.
    2013 Jun
    30(2):501.
  43. Diagnosis, prognosis, and management of leiomyosarcoma: recognition of anatomic variants.
    Bathan AJ, Constantinidou A, Pollack SM, Jones RL
    Curr Opin Oncol
    2013 Jul
    25(4):384-9.
  44. An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma.
    Newman EN, Jones RL, Hawkins DS
    Pediatr Blood Cancer
    2013 Jul
    60(7):1113-7.
  45. Role of the antiapoptotic proteins BCL2 and MCL1 in the neonatal mouse ovary.
    Jones RL, Pepling ME
    Biol. Reprod.
    2013 Feb
    88(2):46.
  46. The evolution of systemic therapy in sarcoma.
    Constantinidou A, Pollack S, Loggers E, Rodler E, Jones RL
    Expert Rev Anticancer Ther
    2013 Feb
    13(2):211-23.
  47. Management of gastrointestinal stromal tumors.
    Rajendra R, Pollack SM, Jones RL
    Future Oncol
    2013 Feb
    9(2):193-206.
  48. Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates.
    Meyer JM, Perlewitz KS, Hayden JB, Doung YC, Hung AY, Vetto JT, Pommier RF, Mansoor A, Beckett BR, Tudorica A, Mori M, Holtorf ML, Afzal A, Woodward WJ, Rodler ET, Jones RL, Huang W, Ryan CW
    Clin. Cancer Res.
    2013 Dec 15
    19(24):6902-11.
  49. The efficacy of caffeine-potentiated chemotherapy in clear cell sarcoma.
    Jones RL, Constantinidou A
    Int. J. Clin. Oncol.
    2013 Apr
    18(2):356.
  50. Multiple liver abscess formation and primary gastrointestinal stromal tumor.
    Chang AE, Mann GN, Hoch B, Loggers ET, Pollack SM, Kolokythas O, Jones RL
    Rare Tumors
    2013
    5(3):e51.
  51. Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib.
    Rajendra R, Jones RL, Pollack SM
    Onco Targets Ther
    2013
    6:217-22.
  52. Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma.
    Martin-Liberal J, Alam S, Constantinidou A, Fisher C, Khabra K, Messiou C, Olmos D, Mitchell S, Al-Muderis O, Miah A, Linch M, Jones RL, Scurr M, Judson I, Benson C
    Sarcoma
    2013
    2013:868973.
  53. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.
    Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee C
    Cancer
    2012 Sep 15
    118(18):4564-70.
  54. Reducing maternal deaths through state maternal mortality review.
    Kilpatrick SJ, Prentice P, Jones RL, Geller S.
    J Womens Health (Larchmt). 2012
    2012 Sep
    21(9):905-9. doi: 10.1089/jwh.2011.3398. Epub 2012 May 23.
  55. Systemic therapy in primary angiosarcoma of the spleen.
    Ferreira BP, Rodler ET, Loggers ET, Pollack SM, Jones RL
    Rare Tumors
    2012 Oct 10
    4(4):e55.
  56. MDM2 inhibition in liposarcoma: a step in the right direction.
    Constantinidou A, Pollack SM, Jones RL
    Lancet Oncol.
    2012 Nov
    13(11):1070-1.
  57. The effects of concurrent cognitive load on phonological processing in adults who stutter.
    Jones RM, Fox RA, Jacewicz E
    J. Speech Lang. Hear. Res.
    2012 Dec
    55(6):1862-75.
  58. Effect of screening for partner violence on women's quality of life: a randomized controlled trial.
    Klevens J, Kee R, Trick W, Garcia D, Angulo FR, Jones R, Sadowski LS.
    JAMA. 2012
    2012 Aug 15
    308(7):681-9. doi: 10.1001/jama.2012.6434.
  59. Role of palliative chemotherapy in advanced epithelioid sarcoma.
    Jones RL, Constantinidou A, Olmos D, Thway K, Fisher C, Al-Muderis O, Scurr M, Judson IR
    Am. J. Clin. Oncol.
    2012 Aug
    35(4):351-7.
  60. Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour.
    Constantinidou A, Jones RL, Olmos D, Thway K, Fisher C, Al-Muderis O, Judson I
    Acta Oncol
    2012 Apr
    51(4):550-4.
  61. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.
    Pollack SM, Li Y, Blaisdell MJ, Farrar EA, Chou J, Hoch BL, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee C
    PLoS ONE
    2012
    7(2):e32165.
  62. Chemotherapy in clear cell sarcoma.
    Jones RL, Constantinidou A, Thway K, Ashley S, Scurr M, Al-Muderis O, Fisher C, Antonescu CR, D'Adamo DR, Keohan ML, Maki RG, Judson IR
    Med. Oncol.
    2011 Sep
    28(3):859-63.
  63. Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer.
    Dedes KJ, Natrajan R, Lambros MB, Geyer FC, Lopez-Garcia MA, Savage K, Jones RL, Reis-Filho JS
    Eur. J. Cancer
    2011 Jan
    47(1):138-50.
  64. Fungal spinal cord compression in metastatic synovial sarcoma.
    Ratnayake G, Judson IR, Scurr M, Thway K, Fisher C, Jones RL
    Acta Oncol
    2011 Jan
    50(1):158-9.
  65. Nuclear NF-?B/p65 expression and response to neoadjuvant chemotherapy in breast cancer.
    Jones RL, Rojo F, A'Hern R, Villena N, Salter J, Corominas JM, Servitja S, Smith IE, Rovira A, Reis-Filho JS, Dowsett M, Albanell J
    J. Clin. Pathol.
    2011 Feb
    64(2):130-5.
  66. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.
    Sanfilippo R, Grosso F, Jones RL, Banerjee S, Pilotti S, D'Incalci M, Dei Tos AP, Raspagliesi F, Judson I, Casali PG
    Gynecol. Oncol.
    2011 Dec
    123(3):553-6.
  67. Clinical benefit of early phase clinical trial participation for advanced sarcoma patients.
    Jones RL, Olmos D, Thway K, Fisher C, Tunariu N, Postel-Vinay S, Scurr M, de Bono J, Kaye SB, Judson IR
    Cancer Chemother. Pharmacol.
    2011 Aug
    68(2):423-9.
  68. Mental health, criminal justice and culture: some ways forward?
    Jones R, Day A
    Australas Psychiatry
    2011 Aug
    19(4):325-30.
  69. Advanced aggressive fibromatosis: Effective palliation with chemotherapy.
    Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I
    Acta Oncol
    2011 Apr
    50(3):455-61.
  70. Immune-based therapies for sarcoma.
    Pollack SM, Loggers ET, Rodler ET, Yee C, Jones RL
    Sarcoma
    2011
    2011:438940.
  71. Acute liver toxicity with ifosfamide in the treatment of sarcoma: a case report.
    Cheung MC, Jones RL, Judson I
    J Med Case Rep
    2011
    5:180.
  72. Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations.
    Olmos D, Martins AS, Jones RL, Alam S, Scurr M, Judson IR
    Sarcoma
    2011
    2011:402508.
  73. Atypical metastatic profile in Stewart-Treves syndrome.
    Almond MH, Jones RL, Thway K, Fisher C, Moskovic E, Judson IR
    Acta Oncol
    2010 Nov
    49(8):1388-90.
  74. Demand-side factors related to employment of people with disabilities: a survey of employers in the midwest region of the United States.
    Chan F, Strauser D, Maher P, Lee EJ, Jones R, Johnson ET
    J Occup Rehabil
    2010 Dec
    20(4):412-9.